Market Analysis
Concomitant with new drug launches from 2009 onwards, HCV market estimated to double by 2010
Published in Health and Medicine Week, August 14th, 2006
An estimated 10 million people in the seven major markets have chronic HCV. The current standard of care, pegylated interferon (Peg-IFN) plus ribavirin (RBV), achieves long-term disease remission in approximately half of those receiving treatment. More efficacious therapies are required to improve treatment success in difficult-to-treat patients, in particular patients with HCV genotype 1.
Scope of this title:
- Comprehensive overview of compounds in clinical development for HCV,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
More Articles from Health and Medicine Week
- Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder associated with reduced sleep instability - Behavioral Medicine
Night eating syndrome may be related to sleep maintenance insomnia - Hair Development
miRNA-processing enzyme dicer essential for hair follicle morphogenesis and maintenance - Ophthalmology
Researchers estimate that the human retina can transmit visual input at the same rate as an Ethernet connection - Wound Care
Drinking water could be a cheap and effective way to clean wounds - Addiction Medicine
Amphetamine-associated cardiotoxicity has medicolegal implications - More from this issue of Health and Medicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
